ALNYLAM PHARMACEUTICALS, INC.

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
AMVUTTRA	approved	$1.0BQ2 2026	1	approved
GIVLAARI	approved	$89.8MQ2 2026	0	—
OXLUMO	approved	$52.1MQ2 2026	0	—
ONPATTRO	approved	$18.5MQ2 2026	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (69)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02292186	phase2	completed	2014-10-01	2017-02-22	Alnylam Pharmaceuticals	A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
NCT02452372	phase1	completed	2015-05-06	2017-09-06	Alnylam Pharmaceuticals	A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
NCT02314442	phase1	completed	2014-12-01	2015-05-01	Alnylam Pharmaceuticals	A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT01814839	phase1	completed	2013-03-01	2015-04-01	Alnylam Pharmaceuticals	A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
NCT02352493	phase1_2	completed	2015-01-01	2016-04-01	Alnylam Pharmaceuticals	A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 215515

2022-06-13

NDA

ALNYLAM PHARMACEUTICALS INC

NDA 214103

2020-11-23

NDA

ALNYLAM PHARMACEUTICALS INC

NDA 212194

2019-11-20

NDA

ALNYLAM PHARMACEUTICALS INC

NDA 210922

2018-08-10

NDA

ALNYLAM PHARMACEUTICALS INC